A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

N/ANot Yet RecruitingNCT06682247

Feng Wang200 enrolled

Overview

This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Colorectal Cancer Metastatic

Interventions

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitorsDRUG

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Aged≥18 years 2. Histology-confirmed metastatic CRC (mCRC); 3. ECOG 0\~2 4. At least one efficacy evaluation 5. Life expectancy of at least 3 months. Exclusion Criteria: 1. Lack of follow-up data. 2. Chidamide stopped after less than two cycles. 3. Serious comorbidities that interfere with the efficacy or safety analysis

Outcomes

Primary Outcomes

Progression-free survival(PFS)

Time frame: 2 years

Secondary Outcomes

Objective Response Rate（ORR）

Time frame: 2 years

Clinical Benefit Rate (CBR)

Time frame: 2 years

Disease Control Rate （DCR）

Time frame: 2 years

Overall survival (OS)

Time frame: 2 years

Central Contacts

feng wang

CONTACT

020-87343088 wangfeng@sysucc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.